Silent Adrenal Pheochromocytoma Coexistent with Corticomedullary Hyperplasia: A Case Incidentally Discovered

Article · October 2017
DOI: 10.12890/2017_000714

8 authors, including:

Luigi Petramala
Sapienza University of Rome
114 PUBLICATIONS 1,085 CITATIONS

Antonio Concistré
Sapienza University of Rome
34 PUBLICATIONS 91 CITATIONS

Gino Iannucci
Sapienza University of Rome
55 PUBLICATIONS 178 CITATIONS

Antonio Ciardi
Sapienza University of Rome
126 PUBLICATIONS 1,720 CITATIONS

Some of the authors of this publication are also working on these related projects:

Multiparametric MRI in prostate carcinoma View project
Parathyroid MRI View project

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/320257464
Silent Adrenal Pheochromocytoma Coexistent with Corticomedullary Hyperplasia: A Case Incidentally Discovered

Luigi Petramala¹, Antonio Concistrè¹, Federica Olmati¹, Vincenza Saraceno¹, Gino Iannucci¹, Antonio Ciardi², Giorgio De Toma², Claudio Letizia¹

¹Specialized Center of Secondary Hypertension, Department of Internal Medicine and Medical Specialties, University “Sapienza”, Rome, Italy
²Department of Surgery “Pietro Valdoni”, University “Sapienza”, Rome, Italy

Received: 27/07/2017
Accepted: 04/08/2017
Published: 06/10/2017

How to cite this article: Petramala L, Concistrè A, Olmati F, Saraceno V, Iannucci G, Ciardi A, De Toma G, Letizia C. Silent adrenal pheochromocytoma coexistent with corticomedullary hyperplasia: a case incidentally discovered. EJCRIM 2017;4: doi:10.12890/2017_000714.

Conflicts of Interests: The Authors declare that there are no competing interests.
This article is licensed under a Commons Attribution Non-Commercial 4.0 License

ABSTRACT
Introduction: Pheochromocytoma (PHEO) is a rare catecholamine-producing tumour arising from chromaffin cells in the sympatho-adrenal system, and can present as asymptomatic adrenal incidentaloma (AI).
Patient: We describe the case of a 61-year-old woman with a right adrenal mass incidentally discovered, who was biochemically characterized with subclinical hypercortisolism (SH). The patient was scheduled for adrenalectomy because of increasing seizure of the right adrenal gland with a haemorrhagic and focal pseudocystic appearance macroscopically, incidental histological and immunohistochemical PHEO, and micronodular cortico-adrenal hyperplasia.
Discussion: This report describes a rare case of incidental non-functioning PHEO coexisting with corticomedullary hyperplasia and SH.

LEARNING POINTS
• Rare presentation of coexisting common (adrenal incidentaloma and subclinical Cushing’s syndrome) and uncommon (pheochromocytoma) endocrinological conditions.

KEYWORDS
Adrenal incidentaloma, subclinical hypercortisolism, pheochromocytoma, adrenal hyperplasia

INTRODUCTION
Pheochromocytoma (PHEO) is a rare catecholamine-producing tumour arising from chromaffin cells in the sympatho-adrenal system, and has a prevalence of 0.1–0.6%[1]. Hypertension, either paroxysmal or sustained, is the most consistent finding in PHEO, and the classic triad of symptoms (headache, palpitations and diaphoresis) is present in more than 50% of patients[2]. However, PHEO can present as asymptomatic adrenal incidentaloma (AI) revealed during abdominal imaging.

CASE REPORT
In May 2016, a 61-year-old woman was referred to our centre for evaluation of a right adrenal mass (diameter 44 mm) and arterial hypertension. She did not complain of any relevant symptoms. In July 2010, the patient had been evaluated in another hospital with an incidental finding of a right adrenal mass (diameter 28 mm) (Fig. 1), with biochemical and hormonal corticomедullary findings in the normal
range (Table 1). The patient was treated with ramipril (10 mg/day) and amlodipine (10 mg/day). On physical examination, the patient’s heart rate was 61 bpm and her blood pressure (BP) was 150/90 mmHg without postural drop, her BMI was 30.7 kg/m², and she had a waist circumference of 107 cm. No signs of hypercortisolism, such as buffalo hump, moon face, striae or skin abnormalities, were seen. Ambulatory blood pressure monitoring (ABPM) revealed a global mean BP of 135/85 mmHg without a drop in nocturnal BP (non-dipping profile). The EKG was unremarkable. Routine blood tests were normal. Hormonal evaluation was performed after adequate preparation (Table 1). In particular, urinary free cortisol (UFC) and plasma cortisol (PC) following an overnight dexamethasone test were high and associated with a low plasma ACTH value. A diagnosis of subclinical hypercortisolism (SH) was made, and considering the increasing diameter of the adrenal mass, the patient underwent a laparoscopic adrenalectomy. Intraoperatively, the patient did not experience any haemodynamic alterations. The post-operative course was uneventful, and the patient was discharged from hospital on a cortisol substitute and attended regular follow-up appointments.

Table 1. Endocrinological data of the patient 6 years before diagnosis, at diagnosis and 6 months after laparoscopic removal of the tumour

|                    | July 2010 | May 2016 | December 2016 | Normal Values |
|--------------------|-----------|----------|---------------|---------------|
| **Serum**          |           |          |               |               |
| Plasma aldosterone (pg/ml) | 128       | 106      | 86            | 30-160        |
| Plasma cortisol (mg/dl)   | 11        | 15.6     | 14.7          | 6-23          |
| Plasma renin activity (ng/ml/h) | 3         | 0.4      | 1.2           | 0.5-3         |
| ACTH (pg/ml)         | 19        | 7        | 22            | 8-50          |
| Plasma cortisol after 1 mg of dexamethasone (overnight test) | -         | 3.5      | -             | <1.8          |
| **Urine**           |           |          |               |               |
| Urinary free cortisol (mg/24 h) | 160       | 256.8    | 198.2         | 38-208        |
| Urinary mandelic acid (mg/24 h) | 5         | 6.6      | 5.3           | 0-10.6        |
| Urinary total catecholamine (mg/24 h) | 70       | -        | -             | -             |
| Urinary aldosterone secretion (mg/24 h) | -         | 13.9     | 8.6           | 2.84-34       |
| Urinary total metanephrines (mg/24 h) | -         | 264      | 55            | 20-350        |

Figure 1. Computed tomography of the abdomen showing an incidental finding of a right adrenal mass (diameter 28 mm)
PATHOLOGICAL EXAMINATIONS
Macroscopically, the right adrenal gland measured 6×4×3.2 cm and was a rusty-coloured nodule with a haemorrhagic and focal pseudocystic appearance. The remnant adrenal gland had a cortex with a micronodular pattern around a widened greyish medulla. Histology revealed a lesion with tumour cells arranged in well-defined nests. The nuclei were round or oval with prominent nucleoli, occasionally containing inclusion-like striatures (cytoplasmic invaginations). The mitotic rate was 3/10 HPF (Fig. 2). No necrosis or vascular invasion was recorded. A multinodular pattern was observed in the residual cortex, with an obvious zona fasciculata. The medulla of the normal gland showed widening (cortex/medulla ratio < 10:1), with cells arranged in a nest. Immunohistochemistry using antibody against chromogranin, synaptophysin and neuron-specific enolase showed positive results, but anti-inhibin was negative. S-100 protein immunoreactivity showed a conspicuous number of substentacular cells. Immunohistochemical studies using antibody against ACTH were positive in the adrenal cortex and medulla (Fig. 3). A final diagnosis was made of adrenal PHEO accompanied by micronodular cortico-medullary hyperplasia. The patient was examined 6 and 12 months post-operatively and showed normal adrenal hormone values (Table 1). No further cortisol treatment was given.

DISCUSSION
This report describes a rare case of incidental non-functioning PHEO coexisting with corticomedullary hyperplasia and SH. Approximately 5–6.5% of AI are PHEO, and a few rare patients with PHEO are completely asymptomatic[1, 2]. In our patient, none of the specific signs and symptoms of hyperproduction of catecholamines were present at diagnosis. The clinical and biohumoral presentation of PHEO depends on the ability of the neoplasm to synthetize, metabolize and release different catecholamines and their metabolites. A tumour predominantly secreting epinephrine is usually associated with paroxysmal hypertension, while the norepinephrine variant is associated with sustained hypertension[3]. The lack of classic features of PHEO in our patient can be explained by the repeated normal urinary metanephrines. Hormonal evaluation revealed autonomous glucocorticoid production without specific signs and symptoms of hypercortisolism[4]. Histopathological examination of the adrenal mass revealed PHEO associated with corticomedullary hyperplasia. The results of this study suggest that the adrenal medulla is not only influenced by the cortex but also influences the cortex directly or through the systemic circulation[5]. In particular, we hypothesize that the presence of immunoreactive ACTH in PHEO may be a possible cause of adrenocortical hyperplasia.

In conclusion, we present a rare case of silent adrenal PHEO incidentally discovered and associated with SH with corticomedullary hyperplasia.
REFERENCES

1. Tischler AS, Pacak K, Eisenhofer G. The adrenal medulla and extra-adrenal paraganglia: then and now. Endocr Pathol 2014;25:49–58.
2. Cotesta D, Petramala L, Serra V, Pergolini M, Crescenzi E, Zinnamosca L, et al. Clinical experience with pheochromocytoma in a single centre over 16 years. High Blood Press Cardiovasc Prev 2009;16:183–193.
3. Mannelli M, Lenders JW, Pacak K, Parenti G, Eisenhofer G. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab 2012;26:507–515.
4. Petramala L, Cavallaro G, Galassi M, Marinelli C, Tonnarini G, Concistrè A, et al. Clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism due to adrenal incidentaloma: results from a single center. High Blood Press Cardiovasc Prev 2017;24:69–75.
5. Lefebvre H, Thomas M, Duparc C, Bertherat J, Louiset E. Role of ACTH in the interactive/paracrine regulation of adrenal steroid secretion in physiological and pathophysiological conditions. Front Endocrinol (Lausanne) 2016;7:98.